Emerging role of GLP-1 receptor agonists in the treatment of obesity

Emerging role of GLP-1 receptor agonists in the treatment of obesity

Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades,...

Full description

Bibliographic Details
Main Author:	Neff LM
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-07-01
Series:	Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:	obesity GLP-1 exenatide liraglutide
Online Access:	https://www.dovepress.com/emerging-role-of-glp-1-receptor-agonists-in-the-treatment-of-obesity-peer-reviewed-article-DMSO

Similar Items

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2021-01-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Young Min Cho, et al.
Published: (2013-12-01)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
by: Ebdrup Bjørn H, et al.
Published: (2012-08-01)

Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R
by: Ziyi Li, et al.
Published: (2020-10-01)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017-03-01)

Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
by: Eva W. Iepsen, et al.
Published: (2020-04-01)

Clinical and laboratory characteristics of exenatide-given patients in endocrinology clinic of a university hospital
by: Faruk Kılınç, et al.
Published: (2014-03-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
by: Mala Dharmalingam, et al.
Published: (2011-01-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020-06-01)

The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
by: Qihong Que, et al.
Published: (2019-06-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)

Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
by: Natia Peradze, et al.
Published: (2019-10-01)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
by: Dario Giugliano, et al.
Published: (2021-09-01)

Efficacy and Safety of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus Treatment: Systematic Review
by: Ana Paula Martins, et al.
Published: (2016-04-01)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
by: Lalita Prasad-Reddy, et al.
Published: (2015-07-01)

Effects of liraglutide on obesity-associated functional hypogonadism in men
by: M Jensterle, et al.
Published: (2019-02-01)

Addendum 2: Forum for Injection Technique, India
by: Sanjay Kalra, et al.
Published: (2014-01-01)

Glucagon-like peptide-1 (GLP-1) and liraglutide, a synthetic GLP-1 analog, inhibit inflammation in human aortic endothelial cells via calcium and AMPK dependent mechanisms
by: Krasner, Nadia Marie
Published: (2016)

Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
by: Rosalie Koot, et al.
Published: (2017-10-01)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
by: Anna Thorsø Larsen, et al.
Published: (2021-01-01)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
by: Martin AA, et al.
Published: (2016-05-01)

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
by: Mariana Cornelia Tilinca, et al.
Published: (2021-06-01)

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway
by: Yi Bao, et al.
Published: (2015-07-01)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
by: Louise Vedtofte, et al.
Published: (2020-10-01)

A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth
by: Hee Young Kim, et al.
Published: (2014-09-01)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
by: Noura Al-Zamel, et al.
Published: (2019-07-01)

Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways
by: Yi-Chia Wu, et al.
Published: (2019-07-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

GLP-1 based therapeutics: Simultaneously combating T2DM and obesity
by: Kristy M Heppner, et al.
Published: (2015-03-01)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
by: Neil Tanday, et al.
Published: (2021-05-01)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
by: Xin Zhao, et al.
Published: (2021-08-01)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
by: David C. D. Hope, et al.
Published: (2021-09-01)